Electrochemical Microfluidic Paper-Based Aptasensor Platform Based on a Biotin-Streptavidin System for Label-Free Detection of Biomarkers
Electrochemical Microfluidic Paper-Based Aptasensor Platform Based on a Biotin-Streptavidin System for Label-Free Detection of Biomarkers
复制标题
基于生物素-链霉亲和素系统的电化学微流体纸基适体传感器平台，用于无标记检测生物标志物
DOI：
10.1021/acsami.1c12716
复制
发表时间：
2021-09-21
影响因子：
9.5
通讯作者：
Cai, Xinxia
中科院分区：
文献类型：
--
作者：
Ming, Tao;Cheng, Yan;Cai, Xinxia
及时、快速地检测生物标志物对于疾病的诊断和治疗极为重要。不过，去医院检测生物标志物是最常见的方式。人们需要花费大量的金钱和时间进行各种测试，以检测潜在的疾病。为了使检测更加方便和实惠，我们提出了一个基于纸张的适体传感器平台在这项工作中。该装置基于纤维素纸，在其上制造三电极系统和微流体通道。同时，合成了氨基氧化还原石墨烯/硫代硫酸钠/链霉亲和素修饰的金纳米粒子/壳聚糖纳米材料，并将其修饰在器件的工作电极上。通过生物素-链霉亲和素系统，5 '端修饰有生物素的适体可以牢固地固定在电极上。检测原理是由于生物标志物及其适体的组合，由纳米材料产生的电流与靶的浓度成比例地降低。17 β-雌二醇（17 beta-E2）作为广泛应用于各种临床状况的诊断生物标志物之一，用于验证平台的性能。实验结果表明，该装置可用于17 β-E2的测定，线性范围为10 pg mL（-1）~ 100 ng mL（-1），检出限为10 pg mL（-1）（S/N = 3）。此外，它能够检测临床血清样品中的靶标，证明其有可能成为用于检测各种生物标志物的一次性和方便的集成平台。
Timely and rapid detection of biomarkers is extremely important for the diagnosis and treatment of diseases. However, going to the hospital to test biomarkers is the most common way. People need to spend a lot of money and time on various tests for potential disease detection. To make the detection more convenient and affordable, we propose a paper-based aptasensor platform in this work. This device is based on a cellulose paper, on which a three-electrode system and microfluidic channels are fabricated. Meanwhile, novel nanomaterials consisting of amino redox graphene/thionine/streptavidin-modified gold nanoparticles/chitosan are synthesized and modified on the working electrode of the device. Through the biotin-streptavidin system, the aptamer whose 5'end is modified with biotin can be firmly immobilized on the electrode. The detection principle is that the current generated by the nanomaterials decreases proportionally to the concentration of targets owing to the combination of the biomarker and its aptamer. 17 beta-Estradiol (17 beta-E2), as one of the widely used diagnostic biomarkers of various clinical conditions, is adopted for verifying the performance of the platform. The experimental results demonstrated that this device enables the determination of 17 beta-E2 in a wide linear range of concentrations of 10 pg mL(-1) to 100 ng mL(-1) and the limit of detection is 10 pg mL(-1) (S/N = 3). Moreover, it enables the detection of targets in clinical serum samples, demonstrating its potential to be a disposable and convenient integrated platform for detecting various biomarkers.